# XALute (NCT06691984)

> Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

No report yet. It can be ordered.

- Drugs tested: xaluritamig
- Indication: metastatic castration-resistant prostate cancer previously treated with chemotherapy

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06691984
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Amgen
- Conditions: Metastatic Castration-resistant Prostate Cancer
- Interventions: Xaluritamig; Abiraterone; Enzalutamide; Cabazitaxel
- Enrollment: 707
- Primary outcome: Overall Survival (OS)

## Indexed commentary on XALute so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=xalute-nct06691984